Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL ER versus METRONIDAZOLE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL ER versus METRONIDAZOLE IN PLASTIC CONTAINER.
FLAGYL ER vs METRONIDAZOLE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
After intracellular reduction, metronidazole and its metabolites interact with DNA leading to inhibition of nucleic acid synthesis and cell death. It is active against anaerobic bacteria and protozoa.
750 mg orally once daily for 10 days for bacterial vaginosis.
500 mg IV every 8 hours or 7.5 mg/kg IV every 6 hours (loading dose 15 mg/kg) for most anaerobic infections.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
8 hours (range 6-12 hours) in adults with normal hepatic function; prolonged to 15-30 hours in severe liver disease
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (<5%)
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic